
    
      This first-in-human (FIH) study will investigate the safety, tolerability, pharmacokinetics
      (PK) and pharmacodynamics (PD) of SLN124 after single ascending s.c. doses in healthy male
      and female subjects.

      Up to 3 cohorts of 24 healthy volunteers will be enrolled. Each subject will receive a single
      dose of SLN124 or placebo given by subcutaneous (s.c) injection.
    
  